期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 21, 期 -, 页码 434-450出版社
CELL PRESS
DOI: 10.1016/j.omtm.2021.03.021
关键词
-
资金
- National Institutes of Health [S10OD023527]
- Veterans Affairs Merit Award from the Department of Veterans Affairs [BX003671]
- National Institutes of Health, Bethesda, MD, USA [NS073653, GM085179, R56AG057469, R01NS109075]
- Penn AD Core Center grant [AG-10124-28]
The study identified that decreased expression of the synaptic plasticity protein caveolin-1 may contribute to learning and memory deficits in Alzheimer's disease. Gene therapy targeted at PSAPP mice was able to improve learning and memory, neuronal structure, and maintain lipid raft profiles. This research suggests that gene therapy could be a potential option for treating Alzheimer's disease.
Alzheimer's disease (AD) is the most common form of neurodegeneration and cognitive dysfunction in the elderly. Identifyingmolecular signals that mitigate and reverse neurodegeneration in AD may be exploited therapeutically. Transgenic AD mice (PSAPP) exhibit learning and memory deficits at 9 and 11 months, respectively, with associated decreased expression of caveolin-1 (Cav-1), a membrane/lipid raft (MLR) scaffolding protein necessary for synaptic and neuroplasticity. Neuronal-targeted gene therapy using synapsin-Cav-1 cDNA (SynCav1) was delivered to the hippocampus of PSAPP mice at 3 months using adeno-associated virus serotype 9 (AAV9). Bilateral SynCav1 gene therapy was able to preserve MLRs profile, learning and memory, hippocampal dendritic arbor, synaptic ultrastructure, and axonal myelin content in 9- and 11-month PSAPP mice, independent of reducing toxic amyloid deposits and astrogliosis. Our data indicate that SynCav1 gene therapy may be an option for AD and potentially in other forms of neurodegeneration of unknown etiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据